c-Met-IN-23

Cat. No.:	HY-161353
Molecular Formula:	$C_{16}H_{13}N_7O$
Molecular Weight:	319.32
Target:	c-Met/HGFR; P-glycoprotein
Pathway:	Protein Tyrosine Kinase/RTK; Membrane Transporter/Ion Channel
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	c-Met-IN-23 (Compound 12g) is a c-Met inhibitor (IC_{50} = 0.052 μM for c-Met). c-Met-IN-23 also inhibits MDR1 and MRP1/2 pumps in the cancerous HepG2 and BxPC3 cells. c-Met-IN-23 is an anticancer agent[1].
In Vitro	c-Met-IN-23 (72 h) inhibits HGF-induced cell proliferation, with IC_{50}s of 12.4, 3.06, 19.30, 16.85 μM for HT29, HepG2, MCF7, MDA-MB-231 cells respectively[1]. c-Met-IN-23 (0.3-150 μM, 30 min) blocks P-gp and MRP1/2 pumps in both HepG2 and BxPC3 cells[1]. c-Met-IN-23 (3 μM, 24 h) increases the expression of P-gp in HepG2 and BxPC3 cells, as well as MRP1 and MRP2 in BxPC3 cells, and inhibits the P-gp-mediated efflux in HepG2 cell[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Khatir ZZ, et al. 4-{3-[(Pyridin-4-ylmethyl)amino]-[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl}phenol: An improved anticancer agent in hepatocellular carcinoma and a selective MDR1/MRP modulator. Arch Pharm (Weinheim). 2024 Mar 5:e2300704.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA